Rapamycin's Role in Periodontal Health and Therapeutics: A Scoping Review.

V M Joshi, S B G, V Thumbigere-Math, M S Kugaji, E Kandaswamy

Department of Periodontics, School of Dentistry, Louisiana State University Health Sciences Center, New Orleans, LA, USA. · pubmed

Paper

Abstract

Periodontitis is a chronic inflammatory disease that leads to progressive destruction of periodontal tissues and eventual tooth loss, significantly affecting the patient's quality of life. Dysregulated mechanistic target of rapamycin (mTOR) signaling contributes to periodontitis pathogenesis by influencing inflammation, autophagy, senescence, and bone metabolism. Rapamycin, a well-established mTOR inhibitor with geroprotective properties, has emerged as a promising therapeutic candidate in mitigating periodontal inflammation and preserving alveolar bone.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Rapamycin may mitigate periodontal inflammation and preserve alveolar bone through its role as an mTOR inhibitor. The paper is relevant as it explores a therapeutic approach that targets underlying mechanisms of aging-related inflammation and tissue degeneration.

Author of this paper? Send a correction.